Merck’s Isentress on track

A FDA advisory panel recommended the approval of Merck's new HIV drug Isentress yesterday. If approved, it would be the second new novel HIV/AIDS...

A FDA advisory panel recommended the approval of Merck's new HIV drug Isentress yesterday. If approved, it would be the second new novel HIV/AIDS drug since August, the first coming with the approval of Pfizer's Selzentry (or maraviroc). Cohn & Wolfe support Merck on Isentress (or raltegravir), which analysts predict could generate more than $1 billion in sales annually. Under the accelerated review process, a final FDA decision is set for October.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.